Topsalysin Aiding Majority of Prostate Cancer Patients, Early Clinical Trial Results Show

Topsalysin Aiding Majority of Prostate Cancer Patients, Early Clinical Trial Results Show
Sophiris Bio Inc., recently released six-month biopsy data from the first seven prostate cancer patients treated with its drug candidate PRX302 (topsalysin) in a Phase 2a proof-of-concept clinical trial. PRX302 is being developed for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH) and of localized low- to intermediate-risk prostate cancer. PRX302 (topsalysin) is a modified

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , .

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

3 comments

  1. Sharon Steiner says:

    My husband is in stage 4 with cancer migration to his breast and spine bones due to a biopsy. Is it too late for the drug described here?

    • Tim Bossie says:

      We are very sorry to hear about your husband and the migration of the cancer. To answer your question, we do not know for certain and can not give any type of medical advice concerning that. However, we would encourage you to contact your doctor with this information to see what they say.

Leave a Comment

Your email address will not be published. Required fields are marked *